NPT

What NPT does

NPT (Neo-Precision Therapeutics, 株式会社NPT) is a Japan-incorporated clinical-stage biotechnology company founded in November 2018 at the University of Tokyo Institute of Medical Science around Prof. Kenzaburo Tani (pioneer of Japan's first cancer gene therapy in 1998). The company develops personalized neoantigen-based cancer immunotherapies, organized around three platform assets: NPT001-HTY, a personalized dendritic cell vaccine that loads five patient-specific neoantigen peptides onto autologous antigen-presenting cells derived from the patient's own monocytes (Phase I/II trial for esophageal cancer, with patient enrollment starting February 2025 at two Tokyo medical institutions); CVOB, a gene-modified Coxsackievirus B3 oncolytic virus with microRNA-targeting safety inserts (covered by PCT/JP2014/060988 and PCT/JP2018/015986); and the PAPC (Neoantigen Peptide-presenting Cell) vaccine platform. The company addresses an unmet need in patients who undergo cancer gene panel testing but receive no matched therapy, a problem the company estimates affects 80-90% of such patients.

The business model is pre-revenue and approval-dependent: NPT manufactures individualized therapies per patient using their own tumor tissue and blood-derived monocytes, intends to distribute through licensed medical institutions in Japan upon regulatory approval under Japan's regenerative medicine framework, and has no currently commercialized product. Revenue mechanics will be one-time product sales per treatment course post-approval, with no disclosed pricing. The company is currently publicly listed on TOKYO PRO Market (TSE, ticker 311A) but announced a delisting application on April 28, 2026. Capital sources to date include 100 million JPY from Ryukakusan Co., Ltd. (largest corporate investor), approximately 501 individual shareholders via angel networks, a 2022 basic partnership with Zeon Corporation for commercialization support, and two equity crowdfunding rounds via FUNDINNO (December 2022, target hit within ~1 hour) and CF Angels (August 2024, 100 million JPY for clinical trial preparation).

The primary customer segment — patients requiring personalized oncology treatment after genetic panel testing — is served indirectly through clinical trial sites and, eventually, hospital-based administration of approved regenerative medicine products. The company operates with 1-10 employees from a Tokyo headquarters (TOC Ariake East Tower 16F, relocated January 2024) with a registered head office in Fukuoka, maintaining research relationships with the University of Tokyo, Kyushu University, Shinshu University, and Kanazawa Medical University, and counts Prof. Atsushi Miyajima (former Director of Tokyo University Molecular Cell Biology Institute) as external director.

Name

NPT

Legal name

株式会社NPT

Website

https://neopt.jp/

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

NPT (Neo-Precision Therapeutics) is a Japan-based clinical-stage biotechnology company developing personalized neoantigen cancer immunotherapies, including the NPT001-HTY dendritic cell vaccine (Phase I/II for esophageal cancer) and a gene-modified Coxsackievirus B3 oncolytic virus platform, serving cancer patients who lack matched treatment options after genetic panel testing.

Ownership category

akta.pro rank

Product category

Personalized Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Dendritic Cell & Other APC-based Therapies (HLAAABAF), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Personalized cancer immunotherapy
• Dendritic cell vaccines
• Oncolytic virus therapy
• Neoantigen peptide vaccines
• Regenerative medicine products

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical / Biologic Product Development and Commercialization: NPT is a clinical-stage biotech company developing personalized cancer immunotherapies (NPT001-HTY for esophageal cancer, CVOB oncolytic virus therapy). Revenue will be generated upon regulatory approval and commercialization of its regenerative medicine products. The company is currently in the clinical development stage with no commercialized products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

NPT develops personalized cancer immunotherapy products for medical institutions, including NPT001-HTY (a personalized dendritic cell vaccine), CVOB (a Coxsackievirus B3-based oncolytic virus therapy), and PAPC peptide vaccines targeting patient-specific neoantigens. The company also licenses its regenerative medicine product technology and currently runs investigator-initiated clinical studies rather than commercial sales.

Product overview

NPT (Neo-Precision Therapeutics) is a biotechnology company developing personalized cancer immunotherapies. The company's core offerings include NPT001-HTY, a personalized dendritic cell vaccine targeting neoantigens specific to each patient's esophageal cancer, and CVOB, an oncolytic virus therapy based on genetically modified Coxsackievirus B3. NPT001-HTY is manufactured individually for each patient by extracting tumor tissue, analyzing neoantigen peptides, and loading them onto dendritic cells derived from the patient's own monocytes. The company is also developing the PAPC (Neoantigen Peptide-presenting Cell) vaccine platform. These products are classified as regenerative medicine products under Japan's regulatory framework.

Differentiator

Problem solved

Functional benefit

Products and services

• NPT001-HTY (Personalized Dendritic Cell Vaccine) Personalized dendritic cell vaccine (HTY) that targets patient-specific neoantigens for cancer immunotherapy, intended for administration at medical institutions treating oncology patients; currently in investigator-initiated clinical studies.
• CVOB (Coxsackievirus B3-based Oncolytic Virus Therapy) Genetically engineered Coxsackievirus B3-based oncolytic virus therapy designed to selectively target and destroy cancer cells as part of NPT's personalized immunotherapy portfolio; under preclinical and clinical development for oncology use in medical institutions.
• PAPC (Personalized Artificial Peptide Cancer) Vaccine Personalized neoantigen peptide cancer vaccine platform targeting patient-specific tumor neoantigens, forming the third pillar of NPT's personalized cancer immunotherapy offering for eventual use at medical institutions.
• Regenerative Medicine Product Technology Licensing One-time licensing of NPT's regenerative medicine product technology (including personalized immunotherapy platforms) to third-party biotech or pharmaceutical counterparties, generating licensing revenue for the company.

Quantifiable outcome

• Japan's first corporate clinical trial of neoantigen-based cancer immunocellular therapy — Phase I/II for esophageal cancer initiated December 2024
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered major and core.

• Zeon Corporation (日本ゼオン株式会社)majorStrategic or Co-development Partner · 20 October 2022NPT entered into a basic agreement for a capital and business partnership with Zeon Corporation, a major chemical manufacturer specializing in synthetic rubber, synthetic latex, and functional materials. The partnership aims to develop and commercialize products and services related to personalized medicine. Final agreement targeted for March 2023, with negotiations ongoing.
• Prof. Kenzaburo Tani (谷 憲三朗)coreOthersNPT was founded in November 2018 at the Tokyo University Institute of Medical Science (Tokyo Daigaku Ikagaku Kenkyujo) around Prof. Kenzaburo Tani, who served as a specially appointed professor at Tokyo University and was previously Director of Kyushu University's Institute for Frontier Life Sciences. Prof. Tani conducted Japan's first cancer gene therapy in 1998. He serves as a technical advisor and board member (joined as director in January 2025).
• University of Tokyo / Tokyo University of Science / Kyushu University / Shinshu University / Kanazawa Medical University (複数の大学)majorStrategic or Co-development PartnerNPT maintains research partnerships with multiple Japanese universities including Tokyo University (Institute of Medical Science, Quantitative Life Sciences Institute), Kyushu University (Institute for Frontier Life Sciences), Shinshu University (Faculty of Medicine), and Kanazawa Medical University (Regenerative Medicine department). Key researchers including Prof. Shohei Miyamoto, Prof. Shigetaka Shimodaira, and Prof. Hideaki Shimada serve as advisors and clinical collaborators.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• BioNTech: BioNTech acquired Neon Therapeutics and continues to develop individualized neoantigen cancer vaccines (BNT122/iNeST, partnered with Genentech/Roche), with multiple tumor-type programs in clinical development. BioNTech is a leading global competitor in personalized mRNA-based cancer vaccines and shares NPT's neoantigen identification and patient-specific manufacturing paradigm.
• Gritstone bio: Gritstone bio develops GRANITE (personalized neoantigen vaccines using chimpanzee adenovirus and self-amplifying mRNA) and SLATE (off-the-shelf neoantigen vaccines), with clinical programs in colorectal cancer and other solid tumors. It is a direct peer in the personalized neoantigen vaccine space targeting solid tumors with shared patient-specific tumor mutation targeting.
• Moderna: Moderna is developing mRNA-4157, a personalized neoantigen cancer vaccine currently in Phase III (with Merck's pembrolizumab) for melanoma and expanding to other tumor types. It is the most advanced and well-capitalized direct competitor in personalized neoantigen immunotherapy, sharing NPT's core mechanism of identifying patient-specific tumor neoantigens to drive tumor-specific T cell responses.
• Northwest Biotherapeutics: Northwest Biotherapeutics developed DCVax-L, an autologous dendritic cell vaccine platform for glioblastoma and other solid tumors. It is the closest direct mechanistic peer to NPT001-HTY, as both use patient-specific dendritic cells loaded with tumor antigens to drive anti-tumor immune responses — though NPT uses neoantigen peptides while DCVax uses tumor lysate.

Emerging players

• Tessa Therapeutics: Tessa Therapeutics develops autologous and allogeneic cell therapies including virus-specific T cell (VST) therapies for solid tumors and lymphoma, with clinical programs across multiple indications. Tessa shares NPT's focus on personalized cell-based cancer immunotherapy, though using T cell platforms rather than dendritic cell vaccines or oncolytic viruses.
• Adaptimmune Therapeutics: Adaptimmune develops SPEAR T-cell receptor (TCR) therapies targeting solid tumors, with commercial product Tecelra approved for synovial sarcoma. It represents an adjacent personalized cell therapy approach using patient-specific engineered T cells to target tumor antigens — sharing NPT's patient-specific, tumor-targeted immunotherapy paradigm but using a different cell type (T cells vs. dendritic cells).
• Iovance Biotherapeutics: Iovance commercializes Amtagvi (lifileucel), the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma. Iovance is a peer in patient-specific (autologous) cell therapy for solid tumors, sharing NPT's personalized manufacturing paradigm but using TILs rather than dendritic cells or oncolytic viruses.
• Anixa Biosciences: Anixa Biosciences develops cancer immunotherapies including a personalized neoantigen vaccine (with Cleveland Clinic / Dr. Vincent Tuohy) for breast cancer and other solid tumors. It is a small-cap direct peer in personalized neoantigen vaccine development targeting solid tumors, similar in scale and approach to NPT's NPT001-HTY platform.

Regional players

• Takara Bio: Takara Bio is a Japanese biotech with cell and gene therapy capabilities, including TCR-T and other engineered cell therapy platforms, and provides cell processing/CDMO services. As a Japan-based peer with overlapping cell therapy infrastructure and gene therapy expertise, it represents the most credible domestic competitor and potential commercialization partner for NPT.
• Healios K.K. Healios is a Japanese regenerative medicine and cell therapy company developing stem cell therapies (HLCM051 for stroke and ARDS) under Japan's conditional early approval framework. As a domestic regenerative medicine peer operating under the same PMDA regulatory pathways relevant to NPT's products, Healios provides a comparable Japanese regulatory and commercialization template.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks3 records

Key highlights6 records

Customer concentration

• Xtwitter.com/NPT54631835
• YouTubeyoutube.com/channel/UCykxlPBio98LGey2nihYpvQ
• Facebookfacebook.com/profile.php?id=100087224162291
• Instagraminstagram.com/neoprecisiontherapeutics
• LinkedInlinkedin.com/company/npt-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NPT